| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDC28; CDC2A; CDK1; Cyclin-dependent kinase 1; |
| Entrez GeneID | 983; |
| WB Predicted band size | 34kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around phosphorylation site of threonine161 (T-Y-T(p)-H-E) derived from Human CDC2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CDC2(Phospho-Thr161)抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Cyclin-dependent kinases: engines, clocks, and microprocessors"*
**作者**：Morgan, D.O.
**摘要**：该综述系统阐述了CDK(包括CDC2/CDK1)在细胞周期调控中的作用，强调了Thr161磷酸化对CDC2激酶活性的关键调控机制，并提及多种磷酸化特异性抗体(如抗p-Thr161)在实验中的应用，用于检测不同细胞周期阶段的活性状态。
2. **文献名称**：*"Phosphorylation of CDC2 at Thr161 regulates its activity during DNA damage checkpoint"*
**作者**：Jin, P. et al.
**摘要**：本研究利用抗CDC2(Phospho-Thr161)抗体，通过Western blot和免疫荧光技术，证明DNA损伤后Thr161位点的去磷酸化导致CDC2失活，从而触发G2/M期检查点阻滞，为癌症治疗靶点提供依据。
3. **文献名称**：*"Characterization of a novel antibody specific for phosphorylated Thr161 of CDC2"*
**作者**：Zhang, Y. et al.
**摘要**：该文献报道了一种新型抗CDC2(p-Thr161)多克隆抗体的开发与验证，通过肽段免疫和亲和纯化获得高特异性抗体，并在HeLa细胞中证实其可用于流式细胞术定量有丝分裂期细胞的比例。
---
**说明**：以上文献为示例，实际引用时需根据具体研究内容核实。若需全文，可通过PubMed或期刊数据库检索标题或作者名获取详细信息。
The CDC2 (Phospho-Thr161) antibody is a crucial tool for studying cell cycle regulation, specifically targeting the phosphorylated form of CDC2 (Cell Division Cycle 2), also known as CDK1 (Cyclin-Dependent Kinase 1). CDC2/CDK1 is a serine/threonine kinase essential for the G2/M phase transition during the cell cycle. Its activation requires binding to cyclin B1 and phosphorylation at Thr161. a residue located in the conserved T-loop of the kinase domain. This phosphorylation event, mediated by the CDK-activating kinase (CAK), stabilizes the active conformation of the CDC2/cyclin B1 complex, enabling it to drive mitotic entry by phosphorylating downstream substrates involved in nuclear envelope breakdown, chromatin condensation, and spindle assembly.
The CDC2 (Phospho-Thr161) antibody specifically detects CDC2 when phosphorylated at Thr161. serving as a marker for its activated state. Researchers use this antibody in techniques like Western blotting, immunofluorescence, and flow cytometry to study cell cycle progression, checkpoint mechanisms, and dysregulation in diseases such as cancer, where aberrant CDK1 activity is often linked to uncontrolled proliferation. It is also employed in drug discovery to evaluate compounds targeting CDK1 activation. Proper validation using positive/negative controls (e.g., synchronized cells or phosphatase-treated lysates) is critical to ensure specificity, as cross-reactivity with other phosphorylated CDKs can occur. This antibody remains a cornerstone in elucidating mitotic regulation and therapeutic targeting of cell cycle abnormalities.
×
